4. V. Mailander, K. Landfester, Interaction of nanoparticles with cells. Biomacromol 10, 2379–
2400 (2009)
5. C. Fang, M. Zhang, Multifunctional magnetic nanoparticles for medical imaging applications. J. Mater. Chem. 19, 6258–6266 (2009)
6. A.B. de Barros, A. Tsourkas, B. Saboury, V.N. Cardoso, A. Alavi, Emerging role of
radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res. 2, 39 (2012)
7. S. Parveen, R. Misra, S.K. Sahoo, Nanoparticles: a boon to drug delivery, therapeutics,
diagnostics and imaging. Nanomedicine 8, 147–166 (2012)
8. H. Nehoff, N.N. Parayath, L. Domanovitch, S. Taurin, K. Greish, Nanomedicine for drug
targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed.
9, 2539–2555 (2014)
9. S.L. Bellis, Biomaterials Advantages of RGD peptides for directing cell association with
biomaterials. Biomaterials 32, 4205–4210 (2011)
10. A.L. de Barros, L.G. das Mota, C.A. de Ferreira, M.C. de Oliveira, A.M. de Goes,
Cardoso VN. Bombesin derivative radiolabeled with technetium-99 m as agent for tumor
identification. Bioorg. Med. Chem. Lett. 20, 6182–6184
11. A.L. Daugherty, R.J. Mrsny, Formulation and delivery issues for monoclonal antibody
therapeutics. Adv. Drug Deliv. Rev. 58, 686–706 (2006)
12. A. Garcia-Bennett, M. Nees, B. Fadeel, In search of the holy grail: Folate-targeted
nanoparticles for cancer therapy. Biochem. Pharmacol. 81, 976–984 (2011)
13. J.H. Lee, M.V. Yigit, D. Mazumdar, Y. Lu, Molecular diagnostic and drug delivery agents
based on aptamer-nanomaterial conjugates. Adv. Drug Deliv. Rev. 62, 592–605 (2010)
14. K. Knop, R. Hoogenboom, D. Fischer, U.S. Schubert, Poly(ethylene glycol) in drug
delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49,
6288–6308 (2010)
15. J.V. Jokerst, T. Lobovkina, R.N. Zare, S.S. Gambhir, Nanoparticle PEGylation for imaging
and therapy. Nanomedicine (London) 6, 715–728 (2011)
16. S. Goel, C.G. England, F. Chen, W. Cai, Positron emission tomography and nanotechnology: a dynamic duo for cancer theranostics. Adv. Drug Deliv. Rev. 113, 157–176 (2016)
17. D. Sarko, M. Eisenhut, U. Haberkorn, W. Mier, Bifunctional chelators in the design and
application of radiopharmaceuticals for oncological diseases. Curr. Med. Chem. 19, 2667–
2688 (2012)
18. M. Sun, D. Hoffman, G. Sundaresan, L. Yang, N. Lamichhane, J. Zweit, Synthesis and
characterization of intrinsically radiolabeled quantum dots for bimodal detection. Am.
J. Nucl. Med. Mol. Imaging 2, 122–135 (2012)
19. S. Goel, F. Chen, E.B. Ehlerding, W. Cai, Intrinsically radiolabeled nanoparticles: an
emerging paradigm. Small 10, 3825–3830 (2014)
20. W. Cai, H. Hong, In a “nutshell”: intrinsically radio-labeled quantum dots. Am. J. Nucl.
Med. Mol. Imaging 2, 136–140 (2012)
21. S. Goel, F. Chen, S. Luan, H.F. Valdovinos, S. Shi, S.A. Graves et al., Engineering
intrinsically zirconium-89 radiolabeled self-destructing mesoporous silica nanostructures for
in vivo biodistribution and tumor targeting studies. Adv. Sci. 3, 1600122 (2016)
22. H.Y. Yoon, S. Jeon, D.G. You, J.H. Park, I.C. Kwon, H. Koo et al., Inorganic nanoparticles
for image-guided therapy. Bioconjug. Chem. 28(1), 124–134 (2017)
23. J. Conde, J.T. Dias, V. Grazú, M. Moros, P.V. Baptista, J.M. de la Fuente, Revisiting
30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for
nanomedicine. Front. Chem. 2, 48 (2014)
24. M. Longmire, P.L. Choyke, H. Kobayashi, Clearance properties of nano-sized particles and
molecules as imaging agents: considerations and caveats. Nanomedicine (London) 3, 703–
717 (2008)
25. T.F. Massoud, S.S. Gambhir, Molecular imaging in living subjects: seeing fundamental
biological processes in a new light. Genes Dev. 17, 545–580 (2003)
38
C. A. Ferreira et al.
2400 (2009)
5. C. Fang, M. Zhang, Multifunctional magnetic nanoparticles for medical imaging applications. J. Mater. Chem. 19, 6258–6266 (2009)
6. A.B. de Barros, A. Tsourkas, B. Saboury, V.N. Cardoso, A. Alavi, Emerging role of
radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res. 2, 39 (2012)
7. S. Parveen, R. Misra, S.K. Sahoo, Nanoparticles: a boon to drug delivery, therapeutics,
diagnostics and imaging. Nanomedicine 8, 147–166 (2012)
8. H. Nehoff, N.N. Parayath, L. Domanovitch, S. Taurin, K. Greish, Nanomedicine for drug
targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed.
9, 2539–2555 (2014)
9. S.L. Bellis, Biomaterials Advantages of RGD peptides for directing cell association with
biomaterials. Biomaterials 32, 4205–4210 (2011)
10. A.L. de Barros, L.G. das Mota, C.A. de Ferreira, M.C. de Oliveira, A.M. de Goes,
Cardoso VN. Bombesin derivative radiolabeled with technetium-99 m as agent for tumor
identification. Bioorg. Med. Chem. Lett. 20, 6182–6184
11. A.L. Daugherty, R.J. Mrsny, Formulation and delivery issues for monoclonal antibody
therapeutics. Adv. Drug Deliv. Rev. 58, 686–706 (2006)
12. A. Garcia-Bennett, M. Nees, B. Fadeel, In search of the holy grail: Folate-targeted
nanoparticles for cancer therapy. Biochem. Pharmacol. 81, 976–984 (2011)
13. J.H. Lee, M.V. Yigit, D. Mazumdar, Y. Lu, Molecular diagnostic and drug delivery agents
based on aptamer-nanomaterial conjugates. Adv. Drug Deliv. Rev. 62, 592–605 (2010)
14. K. Knop, R. Hoogenboom, D. Fischer, U.S. Schubert, Poly(ethylene glycol) in drug
delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49,
6288–6308 (2010)
15. J.V. Jokerst, T. Lobovkina, R.N. Zare, S.S. Gambhir, Nanoparticle PEGylation for imaging
and therapy. Nanomedicine (London) 6, 715–728 (2011)
16. S. Goel, C.G. England, F. Chen, W. Cai, Positron emission tomography and nanotechnology: a dynamic duo for cancer theranostics. Adv. Drug Deliv. Rev. 113, 157–176 (2016)
17. D. Sarko, M. Eisenhut, U. Haberkorn, W. Mier, Bifunctional chelators in the design and
application of radiopharmaceuticals for oncological diseases. Curr. Med. Chem. 19, 2667–
2688 (2012)
18. M. Sun, D. Hoffman, G. Sundaresan, L. Yang, N. Lamichhane, J. Zweit, Synthesis and
characterization of intrinsically radiolabeled quantum dots for bimodal detection. Am.
J. Nucl. Med. Mol. Imaging 2, 122–135 (2012)
19. S. Goel, F. Chen, E.B. Ehlerding, W. Cai, Intrinsically radiolabeled nanoparticles: an
emerging paradigm. Small 10, 3825–3830 (2014)
20. W. Cai, H. Hong, In a “nutshell”: intrinsically radio-labeled quantum dots. Am. J. Nucl.
Med. Mol. Imaging 2, 136–140 (2012)
21. S. Goel, F. Chen, S. Luan, H.F. Valdovinos, S. Shi, S.A. Graves et al., Engineering
intrinsically zirconium-89 radiolabeled self-destructing mesoporous silica nanostructures for
in vivo biodistribution and tumor targeting studies. Adv. Sci. 3, 1600122 (2016)
22. H.Y. Yoon, S. Jeon, D.G. You, J.H. Park, I.C. Kwon, H. Koo et al., Inorganic nanoparticles
for image-guided therapy. Bioconjug. Chem. 28(1), 124–134 (2017)
23. J. Conde, J.T. Dias, V. Grazú, M. Moros, P.V. Baptista, J.M. de la Fuente, Revisiting
30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for
nanomedicine. Front. Chem. 2, 48 (2014)
24. M. Longmire, P.L. Choyke, H. Kobayashi, Clearance properties of nano-sized particles and
molecules as imaging agents: considerations and caveats. Nanomedicine (London) 3, 703–
717 (2008)
25. T.F. Massoud, S.S. Gambhir, Molecular imaging in living subjects: seeing fundamental
biological processes in a new light. Genes Dev. 17, 545–580 (2003)
38
C. A. Ferreira et al.